

## Eritrea – Measles second dose vaccine support

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Eritrea			
<b>2. Grant Number:</b> 1216-ERI-09A-X			
<b>3. Date of Decision Letter:</b> 9 September 2015			
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2013			
<b>5. Programme Title:</b> NVS, Measles second dose Routine			
<b>6. Vaccine type:</b> Measles			
<b>7. Requested product presentation and formulation of vaccine:</b> Measles, 10 dose(s) per vial, LYOPHILISED			
<b>8. Programme Duration<sup>1</sup>:</b> 2012 -2016			
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>			
	2012-2015	2016	Total <sup>2</sup>
Programme Budget (US\$)	US\$184,920 <sup>3</sup>	US\$55,500	US\$240,420
<b>10. Vaccine Introduction Grant:</b> Not applicable			
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b>			
Type of supplies to be purchased with Gavi funds in each year	2012-2015	2016	
Number of Measles vaccines doses		164,800	
Number of AD syringes		106,800	
Number of re-constitution syringes		18,200	
Number of safety boxes		1,375	
Annual Amounts (US\$)	US\$184,920 <sup>5</sup>	US\$55,500	
<b>12. Procurement agency:</b> UNICEF			

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>13. Self-procurement:</b> Not applicable	
<b>14. Co-financing obligations:</b> Reference code: Not applicable	
<b>15. Operational support for campaigns:</b> Not applicable	
<b>16. Additional documents to be delivered for future disbursements:</b> Not applicable	
Reports, documents and other deliverables	Due dates
<i>APR or its equivalent</i>	To be agreed with Gavi secretariat
<b>17. Financial Clarifications:</b> The Country shall provide the following clarifications to Gavi*: not applicable  <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>	
<b>18. Other conditions:</b> Not applicable	

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
9 September 2015

## Eritrea – PCV Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Eritrea			
2. Grant Number: 1516-ERI-12c-X			
3. Date of Decision Letter: 9 September 2015			
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID			
8. Programme Duration <sup>6</sup> : 2015 - 2016			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2015	2016	Total <sup>7</sup>
Programme Budget (US\$)	US\$969,000 <sup>8</sup>	US\$1,925,000	US\$2,894,000
<b>10. Vaccine Introduction Grant:</b> Not applicable			
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>9</sup></b>			
Type of supplies to be purchased with Gavi funds in each year	2015	2016	
Number of Pneumococcal vaccines doses		383,400	
Number of AD syringes		427,400	
Number of safety boxes		4,725	
Annual Amounts (US\$)	US\$969,000 <sup>10</sup>	US\$1,925,000	
<b>12. Procurement agency:</b> UNICEF			
<b>13. Self-procurement:</b> Not applicable			

<sup>6</sup> This is the entire duration of the programme.

<sup>7</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>8</sup> This is the consolidated amount for all previous years.

<sup>9</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>10</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations:** Reference code: 1516-ERI-12c-X-C

According to the Co-Financing Policy, the Country falls within the group "Initial self-financing".

The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	23,400
Value of vaccine doses (US\$)	US\$76,683
Total Co-Financing Payments (US\$) (including freight)	US\$81,500

**15. Operational support for campaigns:** Not applicable

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
APR or its equivalent	To be agreed with Gavi secretariat

**17. Financial Clarifications:** The Country shall provide the following clarifications to Gavi\*: Not applicable

*\*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
9 September 2015

## Eritrea – Pentavalent Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Eritrea			
2. Grant Number: 16-ERI-04a-X			
3. Date of Decision Letter: 9 September 2015			
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2013			
5. Programme Title: NVS, Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme Duration <sup>11</sup> : 2008 -2016			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2008-2015	2016	Total <sup>12</sup>
Programme Budget (US\$)	US\$6,311,973 <sup>13</sup>	US\$345,500	US\$6,657,473
<b>10. Vaccine Introduction Grant:</b> Not applicable			
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>14</sup></b>			
Type of supplies to be purchased with Gavi funds in each year	2008-2015	2016	
Number of Pentavalent vaccines doses			182,300
Number of AD syringes			206,600
Number of safety boxes			2,275
Annual Amounts (US\$)	US\$6,311,973 <sup>15</sup>		US\$345,500
<b>12. Procurement agency:</b> UNICEF			
<b>13. Self-procurement:</b> Not applicable			

<sup>11</sup> This is the entire duration of the programme.

<sup>12</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>13</sup> This is the consolidated amount for all previous years.

<sup>14</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>15</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations:** Reference code: 16-ERI-04a-X-C

According to the Co-Financing Policy, the Country falls within the group "Initial self-financing".

The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	22,300
Value of vaccine doses (US\$)	US\$40,030
Total Co-Financing Payments (US\$) (including freight)	US\$41,000

**15. Operational support for campaigns:** Not applicable

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
APR or it's equivalent	To be agreed with Gavi secretariat

**17. Financial Clarifications:** The Country shall provide the following clarifications to Gavi\*: Not applicable

*\*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

9 September 2015

## Eritrea – Rotavirus Vaccine Support

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Eritrea			
2. Grant Number: 1316-ERI-13b-X			
3. Date of Decision Letter: 9 September 2015			
4. <b>Date of the Partnership Framework Agreement:</b> 16 April 2013			
5. <b>Programme Title:</b> NVS, Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme Duration <sup>16</sup> : 2014 -2016			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2014-2015	2016	Total <sup>17</sup>
Programme Budget (US\$)	US\$768,000 <sup>18</sup>	US\$511,500	US\$1,279,500
10. <b>Vaccine Introduction Grant:</b> Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement): <sup>19</sup>			
Type of supplies to be purchased with Gavi funds in each year	2014-2015	2016	
Number of Rotavirus vaccines doses		225,000	
Annual Amounts (US\$)	US\$768,000 <sup>20</sup>	US\$511,500	
12. <b>Procurement agency:</b> UNICEF			
13. <b>Self-procurement:</b> Not applicable			

<sup>16</sup> This is the entire duration of the programme.

<sup>17</sup> This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>18</sup> This is the consolidated amount for all previous years.

<sup>19</sup> This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>20</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations:** Reference code: 1316-ERI-13b-X-C  
According to the Co-Financing Policy, the Country falls within the group "Initial self-financing".

The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	78,000
Value of vaccine doses (US\$)	US\$168,760
Total Co-Financing Payments (US\$) (including freight)	US\$173,500

**15. Operational support for campaigns:** Not applicable

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
APR or its equivalent	To be agreed with Gavi secretariat

**17. Financial Clarifications:** The Country shall provide the following clarifications to Gavi\*: Not applicable

*\*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
9 September 2015